First in Europe Turgut Pharmaceuticals
The SR4SB Project, run by Turgut İlaçları A.Ş., was selected as the European First in the 2022 EURIPIDES² Innovation Awards.
That First Day's Vision, Today's Righteous Pride
The Biopharmaceutical facility established by Turgut Pharmaceuticals in Gebze, which developed and produced Turkey's first end-to-end Biosimilar Monoclonal Antibody and completed its Phase 1 study, received the TITCK Approved GMP Certificate.
Turgut Pharmaceuticals, a pioneer in its sector
Turgut Pharmaceuticals continues to draw attention with its success in the health sector and its pioneering position against its competitors.